Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes

Haematologica

Volumn 100, Issue 6, 2015, Pages e220-e222

  Kahn, Josephine D ^b   Chamuleau, Martine E D ^a   Westers, Theresa M ^a   Van de Ven, Peter M ^a   van Dreunen, Linda ^a   van Spronsen, Margot ^a   Ossenkoppele, Gert J ^a   van de Loosdrecht, Arjan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Myelodysplastic syndrome; Progenitor B cells; Prognosis; Regulatory T cells

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; FLOW CYTOMETRY; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOSURVEILLANCE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETTER; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRE B LYMPHOCYTE; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; ADULT; AGED; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; IMMUNOLOGY; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELLS, B-LYMPHOID; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; T-LYMPHOCYTES, REGULATORY;

EID: 84930521042     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.116657     Document Type: Letter

References (11)

1. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012;120(20):2454-2465.
2. Kerkhoff N, Bontkes HJ, Westers TM, et al. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy. Immunotherapy. 2013;5(6):621-637.
3. Kordasti SY, Afzali B, Lim Z, et al. IL-17 producing CD4+ T cells, proinflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145(1):64-72.
4. Chamuleau ME, Westers TM, van Dreunen L, et al. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica. 2009; 94(4):496-506.
5. Kordasti SY, Ingram W, Hayden J, et al. CD4+CD25high FoxP3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110(3):847-850.
6. Hamdi W, Ogawara H, Handa H, et al. Clinical Significance of regulatory T cells in patients with myelodysplastic syndrome. Eur J Haematol. 2008;82(3):201-207.
7. Costantini B, Kordasti SY, Kulasekararaj AG, et al. The effects of 5- azacitidine on the function and number of regulatory T cells and Teffectors in myelodysplastic syndrome. Haematologica. 2013;98(8): 1196-1205.
8. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell Progenitors in early (low-risk) myelodysplastic syndrome. Blood. 2005;106(9):2982-2991.
9. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
10. Mailloux AW, Sugimori C, Komrokji RS, et al. Expansion of Effector Memory Regulatory T cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome. J Immunol. 2012;189(6): 3198-3208.
11. Della Porta MG, Picone C, Pascutto C, et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica. 2012;97(8):1209-1217.